TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation

Citi Removes Two names from 90-Day Catalyst Watch Lists

October 31, 2024 4:06 PM EDT

Citi Removes Two names from 90-Day Catalyst Watch Lists

Tandem Diabetes (NASDAQ: TNDM) Removed from 90-Day Downside Catalyst Watch List: "With our 3Q24 Preview (10/1/24), we opened a 90-day Negative Catalyst Watch on TNDM. The thesis was: 1) survey results suggested ~flat Tandem share of new patient starts in the U.S. in the 3Q24E; 2) while Mobi prescriptions were increasing, it... More

Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

October 30, 2024 4:16 PM EDT

Goldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More

BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)

October 30, 2024 4:03 PM EDT

BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More